Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia

Lupus

Volumn 15, Issue 9, 2006, Pages 600-605

  Garcia Valladares I ^a   Atisha Fregoso, Y ^a   Richaud Patin, Y ^a   Jakez Ocampo, J ^a   Soto Vega, E ^a   Elias Lopez D ^a   Carrillo Maravilla, E ^a   Cabiedes, J ^a   Ruiz Arguelles A ^b   Llorente, Luis ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

Author keywords

Autoantibodies; CD55; CD59; Lymphopenia; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; HYDROXYCHLOROQUINE; PREDNISONE;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; LYMPHOCYTOPENIA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, CD55; ANTIGENS, CD59; B-LYMPHOCYTES; CASE-CONTROL STUDIES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOPENIA; MALE; MIDDLE AGED; SEROLOGIC TESTS; T-LYMPHOCYTES;

EID: 33750519023     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306071916     Document Type: Article

References (24)

1. Osman C, Swaak AJG. Lymphocytotoxic antibodies in SLE: a review of the literature. Clin Rheumatol 1994; 13: 21-27.
2. Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1978; 21: 295-305.
3. Drenkard C, Villa AR, Garcia-Padilla C, Perez-Vazquez ME, Alarcon-Segovia D. Remission of systemic lupus erythematosus. Medicine (Baltimore) 1996; 75: 88-98.
4. Winfield JB. Antilymphocyte autoantibodies. In Wallace DJ, Hahn BH eds. Dubois' lupus erythematosus. Williams and Wilkins, 1997: 505-515.
5. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996; 61: 201-283.
6. Song WC. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr Dir Autoimmun 2004; 7: 181-199.
7. Nicholson-Weller A, Wang CE. Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994; 123: 485-491.
8. Davies A, Lachmann PJ. Membrane defense against complement lysis: The structure and biological properties of CD59. Immunol Res 1993; 12: 258-275.
9. Karadimitris A, Luzzatto L. The cellular pathogenesis of paroxysmal nocturnal hemoglobinuria. Leukemia 2001; 15: 1148-1152.
10. Richaud-Patin Y, Perez-Romano B, Carrillo-Maravilla E et al. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunol Lett 2003; 88: 95-99.
11. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982; 25: 1271-1277.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee of Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
13. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol 2006; 118: 127-136.
14. Nagakura S, Nakakuma H, Horikawa K. Expression of decay-accelerating factor and CD59 in lymphocytes subsets in healthy individual and paroxysmal nocturnal hemoglubinuria patients. Am J Hematol 1993; 43: 14-18.
15. Clarkson NA, Kaufman R, Lublin DM et al. Characterization of the echovirus 7 receptor: domains of CD55 is critical for virus binding. J Virol 1995; 69: 5497-5501.
16. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD. Coxsackie viruses B1, B3 and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995; 69: 3873-3877.
17. Arora M, Arora R, Tiwari SC, Das N, Srivastava LM. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus 2000; 9: 127-131.
18. Cuida M, Legler DW, Eidsheim M, Jonsson R. Complement regulatory proteins in the salivary glands and saliva of Sjögren's syndrome patients and healthy subjects. Clin Exp Rheumatol 1997; 15: 615-623.
19. Li SH, Szmitko PE, Weisel RD et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004; 109: 833-836.
20. van Beek J, van Meurs M, 't Hart VA et al. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol 2005; 174: 2353-2365.
21. Tsunoda S, Kawano M, Koni I et al. Diminished expression of CD59 on activated CD8+ T-cells undergoing apoptosis in systemic lupus erythematosus and Sjögren's syndrome. Scand J Immunol 2000; 51: 293-299.
22. Wenzel J, Gerdsen R, Uerlich M, Bauer R, Tueting T, Bieber T. Lymphocytopenia in lupus erythematosus: close in vivo association to autoantibodies targeting nuclear antigens. Br J Dermatol 2004; 150: 994-998.
23. Böhm I. Apoptosis: The link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol 2004; 33: 409-416.
24. Alarcon-Segovia D, Llorente L, Ruiz-Argüelles A. The penetration of autoantibodies may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage. J Autoimmun 1996; 9: 295-300.